# Type 2 Diabetes: Individualized Pharmacotherapy Beyond Metformin

## Introduction

The management of type 2 diabetes has undergone a paradigm shift. While metformin remains a reasonable first-line agent, the 2022 ADA/EASD consensus and subsequent updates emphasize a **cardiorenal-metabolic approach** where agent selection is driven by comorbidities rather than glucose lowering alone. The emergence of GLP-1 receptor agonists and SGLT2 inhibitors with proven cardiovascular and renal benefits has fundamentally changed the treatment algorithm.

## Glycemic Targets

- **HbA1c < 7%** for most non-pregnant adults (ADA standard target)
- **HbA1c < 6.5%** if achievable without significant hypoglycemia (select younger patients, short disease duration)
- **HbA1c < 8%** for elderly patients, limited life expectancy, extensive comorbidities, or high hypoglycemia risk
- **Time in range (TIR)**: > 70% of time between 70-180 mg/dL on continuous glucose monitoring correlates with HbA1c < 7%

## Metformin: The Traditional Foundation

- **Mechanism**: reduces hepatic glucose production, improves insulin sensitivity
- **Benefits**: low cost, weight neutral to modest weight loss, no hypoglycemia, extensive safety record
- **Limitations**: GI side effects (use extended-release to mitigate), contraindicated if eGFR < 30 mL/min, dose reduction at eGFR < 45
- **Key shift**: ADA 2023 guidelines state that SGLT2i or GLP-1 RA should be initiated for cardiorenal benefit independent of HbA1c and independent of metformin use

## SGLT2 Inhibitors

### Agents and Mechanism

- **Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin**
- Block sodium-glucose cotransporter 2 in the proximal tubule, causing glycosuria
- HbA1c reduction: 0.5-0.8%
- Weight loss: 2-3 kg; systolic BP reduction: 3-5 mmHg

### Cardiovascular and Renal Benefits

- **EMPA-REG OUTCOME**: empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35%
- **DAPA-HF / EMPEROR-Reduced**: benefit in HFrEF regardless of diabetes status
- **CREDENCE / DAPA-CKD**: slowed CKD progression, reduced albuminuria
- **Indications beyond glucose**: HFrEF, HFpEF, CKD with albuminuria (now used in non-diabetic populations)

### Adverse Effects and Precautions

- **Genital mycotic infections** (most common, 5-10%)
- **Euglycemic diabetic ketoacidosis**: rare; hold peri-operatively and during acute illness
- **Volume depletion**: caution in elderly, diuretic use
- Canagliflozin: historical signal for amputations and fractures (not confirmed with other agents)

![Mechanism of action of SGLT2 inhibitors in the nephron](images/sglt2i-mechanism.png)

## GLP-1 Receptor Agonists

### Agents and Mechanism

- **Semaglutide** (subcutaneous weekly, oral daily), **liraglutide** (daily), **dulaglutide** (weekly), **tirzepatide** (dual GIP/GLP-1 agonist, weekly)
- Enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, promote satiety
- HbA1c reduction: 1.0-2.0%; weight loss: 5-15% (tirzepatide up to 20%)

### Landmark Trials

- **SUSTAIN-6 / PIONEER-6**: semaglutide reduced MACE
- **LEADER**: liraglutide reduced cardiovascular death by 22%
- **SURPASS trials**: tirzepatide achieved HbA1c < 5.7% in up to 50% of participants
- **SELECT**: semaglutide 2.4 mg reduced MACE by 20% in patients with obesity and established CVD without diabetes

### Adverse Effects

- **GI symptoms** (nausea, vomiting, diarrhea): dose-escalate gradually to mitigate
- **Pancreatitis**: rare; avoid in patients with prior pancreatitis
- **Thyroid C-cell tumors**: signal in rodents; contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
- **Gallbladder disease**: increased risk with rapid weight loss

![Comparison of GLP-1 RA agents by efficacy and dosing](images/glp1ra-comparison.png)

## Other Agents

### DPP-4 Inhibitors

- **Sitagliptin, linagliptin, saxagliptin, alogliptin**
- Modest HbA1c reduction (0.5-0.7%), weight neutral, well-tolerated
- Cardiovascular safety trials showed neutrality (no benefit, no harm, except saxagliptin and HF risk)
- Role diminishing as GLP-1 RAs become more accessible

### Thiazolidinediones

- **Pioglitazone**: improves insulin sensitivity, durable glucose lowering, NASH benefit (histologic improvement)
- Risks: weight gain, fluid retention, heart failure exacerbation, fractures, bladder cancer concern
- Consider in NASH with insulin resistance if no contraindications

### Insulin

- **Basal insulin** (glargine, degludec): add when oral/injectable agents fail to achieve target
- **Basal-bolus or premixed regimens**: for advanced disease with significant beta-cell failure
- Degludec has lower hypoglycemia risk than glargine U100 (DEVOTE trial)
- **Insulin + GLP-1 RA fixed-ratio combinations** (iDegLira, iGlarLixi): simplify regimens, mitigate insulin-associated weight gain

## The Modern Treatment Algorithm

| Comorbidity | Preferred Agent Class | Key Trials |
|-------------|----------------------|------------|
| ASCVD or high CV risk | GLP-1 RA (semaglutide, liraglutide, dulaglutide) | SUSTAIN-6, LEADER, SELECT |
| Heart failure | SGLT2 inhibitor (empagliflozin, dapagliflozin) | DAPA-HF, EMPEROR-Reduced |
| CKD with albuminuria | SGLT2 inhibitor ± finerenone | DAPA-CKD, CREDENCE, FIDELIO |
| Obesity / weight management | Tirzepatide or semaglutide | SURMOUNT, STEP trials |
| Cost-limited setting | Metformin + sulfonylurea or pioglitazone | Established efficacy data |

1. Assess for **ASCVD, heart failure, or CKD** at diagnosis
2. If ASCVD or high CV risk: **GLP-1 RA** with proven benefit (semaglutide, liraglutide, dulaglutide)
3. If HF: **SGLT2 inhibitor** (empagliflozin, dapagliflozin)
4. If CKD with albuminuria: **SGLT2 inhibitor** (independent of glucose); consider adding **finerenone** (non-steroidal MRA)
5. If primary goal is weight management: **tirzepatide or semaglutide**
6. If cost is a major barrier: **metformin + sulfonylurea or pioglitazone**
7. Reassess HbA1c every 3 months; intensify therapy if above target

![Modern diabetes pharmacotherapy decision algorithm](images/t2dm-treatment-algorithm.png)

## Key Clinical Pearls

- SGLT2 inhibitors and GLP-1 RAs should be prescribed for their cardiorenal benefits independent of HbA1c level
- Tirzepatide (dual GIP/GLP-1 agonist) produces the greatest HbA1c reduction and weight loss of any non-insulin agent
- Hold SGLT2 inhibitors 3-4 days before planned surgery to prevent euglycemic DKA
- Never combine a GLP-1 RA with a DPP-4 inhibitor (redundant mechanism; no added benefit)

## References

1. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the ADA and EASD. *Diabetes Care*. 2022;45(11):2753-2786.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). *N Engl J Med*. 2023;389(24):2221-2232.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). *N Engl J Med*. 2022;387(3):205-216.
4. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). *N Engl J Med*. 2020;383(15):1436-1446.